Immuneering Welcomes Dr. Matushansky as Chief Medical Officer
Industry veteran joins to enhance oncology clinical development
Immuneering, a clinical-stage oncology company dedicated to creating more effective and better tolerated therapies, has announced the appointment of Dr. Igor Matushansky as their new Chief Medical Officer. His extensive experience in oncology drug development and patient care positions him perfectly to lead Immuneering’s clinical initiatives.
Commitment to Cancer Patient Care
Dr. Matushansky takes the helm at a pivotal time for the company as it prepares to present new data from its Phase 2a trial of the candidate IMM-1-104, designed for treating pancreatic cancer. The team at Immuneering is excited about this new chapter under his leadership, knowing he will drive their commitment to developing therapies that not only improve efficacy but also enhance Quality of Life for patients.
“The data we’ve shared emphasize the potential of IMM-1-104 to present a more tolerable and effective option for pancreatic cancer patients,” expressed Ben Zeskind, Ph.D., CEO of Immuneering. His faith in Dr. Matushansky stems from his unique combination of clinical practice and research experience, crucial for understanding the patient experience effectively.
Experience and Credibility in Oncology
Before joining Immuneering, Dr. Matushansky served as Chief Medical Officer at Sail Biomedicines, where he led various functions critical to drug development. His previous role as Senior Vice President and Global Head of Oncology Development at Ipsen Pharmaceuticals was integral in getting NALIRIFOX approved for pancreatic cancer, highlighting his success in moving projects from early-stage research to market.
Dr. Matushansky’s career includes significant contributions at Hookipa Pharma and Daiichi Sankyo, where he was instrumental in performing clinical trials and research in oncology. His educational background is equally impressive, having earned his degrees from prestigious institutions and gained clinical experience at Memorial Sloan Kettering Cancer Center.
Future Directions for Immuneering
Immuneering is on a path to redefine standards in oncology treatment with its lead candidate IMM-1-104, an oral therapy targeting MEK for pancreatic and other challenging tumors. The ongoing clinical trials aim to explore its efficacy further in patients with RAS-driven tumors, providing hope for those who face limited treatment options.
Dr. Matushansky’s expertise will play a vital role as the company plans not just to advance ongoing studies but to initiate pivotal trials in the future. His focus on maintaining quality of life for patients aligns seamlessly with Immuneering's mission to innovate in oncology therapeutics.
Navigating Challenges in Drug Development
Dr. Matushansky recognizes that the journey of oncology drug development is fraught with challenges, including patient safety, efficacy, and rigorous regulatory scrutiny. His substantial experience equips him to address these hurdles effectively, ensuring that Immuneering remains at the forefront of oncology innovation.
About Immuneering Corporation
Immuneering Corporation is pioneering ways to enhance cancer care through advanced therapeutic strategies. Their flagship drug, IMM-1-104, represents a critical advancement in treating challenging cancers, with the company’s pipeline also exploring additional promising approaches. As they move forward, Immuneering remains focused on its goal of transforming cancer treatment and improving patient outcomes.
Contact Information
Media Contact:
Jenna Urban
jurban@cglife.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
Frequently Asked Questions
What role will Dr. Matushansky play at Immuneering?
As Chief Medical Officer, Dr. Matushansky will lead clinical activities and oversee the development of new oncology programs.
What is IMM-1-104 designed to treat?
IMM-1-104 targets pancreatic cancer and aims to provide a better-tolerated option for patients.
Why is Dr. Matushansky's experience significant for Immuneering?
His extensive background in oncology and successful track record in drug development will guide Immuneering's future projects and trial initiatives.
How does Immuneering aim to improve patient care?
Immuneering focuses on creating therapies that not only enhance treatment efficacy but also prioritize the quality of life for cancer patients.
What developments are expected in the coming years from Immuneering?
Immuneering plans to advance ongoing clinical trials and initiate pivotal studies that could broaden treatment options for cancer patients.
